TT
Trefoil Therapeutics
Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$12MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.